Clinical Trial Update: Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone [Phase 2]

View source ↗

Summary

The randomized Phase II study comparing ADT plus Abiraterone versus ADT plus Docetaxel plus Abiraterone in prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Taxotere (docetaxel)

Snippet

Sponsor: Northwestern University | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN